Clinical Trials Logo

Clinical Trial Summary

The LEARN study a multicenter, observational study will that will evaluate the rate of cognitive change in approximately 500 clinically normal older individuals who "screen-fail" for the A4 trial on the basis of their screening PET imaging not demonstrating evidence of elevated amyloid accumulation (Aβ negative) but meet all other A4 study eligibility criteria. This study will leverage the A4 infrastructure and maximize the data acquired in screening a large number of well-characterized older adults for the A4 trial. The LEARN observational cohort will provide a critical comparison group for the A4 placebo arm, and future trials in preclinical AD. Although accumulating longitudinal data suggest that older individuals with elevated Aβ burden are at increased risk of cognitive decline, it is important to demonstrate a differential rate of clinical decline between Aβe ("Aβ elevated") and Aβne ("Aβ not elevated") individuals on a standardized set of clinical outcomes. Over 2000 well-characterized, highly motivated older volunteers will "screen fail" for the A4 trial. The LEARN study will follow 500 of these individuals, matched as closely as possible to the two treatment arms, in this observation cohort. The LEARN study may selectively recruit from a specific range of SUVr that fall below the threshold for "elevated amyloid" in order to support analyses of the relationship of baseline SUVr to subsequent cognitive change and amyloid accumulation. The observational cohort will be followed for 384 weeks with identical clinical/cognitive testing performed every 24 weeks, running parallel to the A4 treatment study and open label extension.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02488720
Study type Observational
Source University of Southern California
Contact
Status Completed
Phase
Start date September 8, 2015
Completion date September 29, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03544801 - Renji Cerebral Small Vessel Disease Corhort Study
Recruiting NCT02813434 - Cerebral Amyloid Imaging Using Florbetapir (AV-45) Phase 3
Completed NCT00400790 - Organ Protection for Coronary Artery Bypass Graft (CABG): Propofol Versus Desflurane N/A
Completed NCT00052091 - Therapy for Depressed Elders With Thought Problems Phase 3
Completed NCT00021866 - Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy N/A
Completed NCT00267163 - Brain Imaging and Mental Disorders of Aging Intervention Phase 4
Not yet recruiting NCT04079075 - Multiple Interventions to Prevent Cognitive Decline N/A
Terminated NCT03696082 - A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines N/A
Completed NCT02918539 - Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Active, not recruiting NCT01708837 - Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction Phase 4
Completed NCT01290939 - Bevacizumab and Lomustine for Recurrent GBM Phase 3
Terminated NCT00548327 - The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype Phase 2
Unknown status NCT00256425 - Cognitive Rehabilitation of Glioma Patients Phase 3
Recruiting NCT03926351 - High Dose Omega 3 in People at Risk for Dementia Phase 2
Completed NCT02118571 - Schizophrenia Cognition Scale Development N/A
Completed NCT01481961 - Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease N/A
Completed NCT00788918 - Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS) N/A
Completed NCT00564902 - The Zeaxanthin and Visual Function Study N/A
Completed NCT00529581 - A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis Phase 2
Terminated NCT04168294 - The Influence of Sedation for Endoscopy on Cognitive Function